Aktis Oncology (AKTS) director Glenn Gormley files initial insider Form 3

Rhea-AI Filing Summary

Aktis Oncology, Inc. director Glenn Gormley filed an initial ownership report on Form 3 for the company’s common stock. The filing lists him as a director but does not report any specific share or derivative holdings at this time and shows no buy or sell transactions.

Key Figures

Buy transactions: 0 Sell transactions: 0 Net buy/sell direction: neutral

3 metrics

Buy transactions 0 Form 3 transaction summary

Sell transactions 0 Form 3 transaction summary

Net buy/sell direction neutral Form 3 transaction summary

Key Terms

Form 3, reporting person, insider status

3 terms

Form 3 regulatory

"Glenn Gormley filed an initial ownership report on Form 3"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

"The filing lists him as a director and reporting person"

insider status regulatory

"now formally reporting his insider status"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Accepted by SEC EDGAR 04/16/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What does the Form 3 filing by Glenn Gormley mean for Aktis Oncology (AKTS)?

The Form 3 shows that Glenn Gormley is a director of Aktis Oncology and is now formally reporting his insider status. It is an administrative disclosure and does not include any stock purchases, sales, or specified holdings.

Does Glenn Gormley report any share transactions in this Form 3 for AKTS?

No, the Form 3 includes no reported share transactions. The transaction summary shows zero buys, zero sells, zero exercises, and no gifts or restructurings, indicating no trading activity is disclosed in this filing.

Are any stock or option holdings reported for Glenn Gormley in the Aktis Oncology Form 3?

No specific holdings are reported. The data show zero holding entries and an empty derivative summary, meaning no common stock or derivative positions are detailed for Glenn Gormley in this particular Form 3 filing.

Does the Aktis Oncology (AKTS) Form 3 show Glenn Gormley buying or selling shares?

No, the filing shows no buying or selling. The transaction summary lists zero buy and sell counts and a net buy/sell direction of neutral, so it functions purely as an initial ownership registration without trading activity.

Is this Form 3 filing by Glenn Gormley significant for AKTS shareholders?

This Form 3 is largely administrative, confirming Glenn Gormley’s role as a director and insider. With no reported holdings or transactions, it does not indicate any change in ownership or trading that would materially affect shareholders.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Gormley Glenn

(Last) (First) (Middle)

C/O AKTIS ONCOLOGY, INC.

17 DRYDOCK AVENUE, SUITE 17-401

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/15/2026

3. Issuer Name and Ticker or Trading Symbol
Aktis Oncology, Inc. [ AKTS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Glenn Gormley	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)